Cold agglutinin disease affects an estimated 5,000 Americans, and separating primary CAD from secondary cold agglutinin syndrome decides who is even eligible for treatment.

Cold agglutinin disease is a rare autoimmune haemolytic anaemia in which a cold-reactive IgM autoantibody binds red blood cells at low temperatures and activates the classical complement pathway through the C1 complex. Complement C3b opsonization then drives mostly extravascular haemolysis in the liver, producing chronic anaemia, profound fatigue and cold-induced circulatory symptoms. Unlike warm autoimmune haemolytic anaemia, this disease is mediated by IgM and the classical complement pathway, which is why complement-directed therapy, not corticosteroids, became the rational treatment target.

The clinical and commercial population divides into primary CAD and secondary cold agglutinin syndrome. Primary CAD is a distinct clonal, low-grade lymphoproliferative bone marrow disorder producing the pathogenic monoclonal IgM; the syndrome is secondary to infection, B-cell lymphoma or another autoimmune disease. A 2016 to 2023 multi-database US claims analysis estimated incidence at 0.6 to 1.2 per 100,000 person-years and one-year prevalence at 1.4 to 3.1 per 100,000, higher in women and rising with age, an order-of-magnitude prevalent pool of roughly 5,000 patients.

Primary CAD and secondary CAS are the same symptom, different diseases.

Five questions this report answers:

Q1 - What is the size and demographic profile of the US CAD population?

Q2 - How does classical complement activation explain hemolysis in cold agglutinin disease?

Q3 - Where does unmet need remain concentrated after sutimlimab's 2022 approval?

Q4 - How common is cold agglutinin disease across the US population?

Q5 - Why does complement inhibition, not corticosteroids, treat cold agglutinin disease?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#ColdAgglutininDisease #CAD #Hematology #RareDisease #AutoimmuneHemolyticAnemia #USHealthcare

Live report page:  https://axlrx.ai/cold-agglutinin-disease/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-           hello@axlrx.ai

Web-           https://axlrx.ai/